How has Oruka Therapeutics, Inc.'s remainder of fiscal year 2024 changed year-over-year?

Oruka Therapeutics, Inc.'s remainder of fiscal year 2024 increased by 108.2% year-over-year, from $306K to $637K.

Oruka Therapeutics, Inc. ORKA Remainder of Fiscal Year 2024

AmgenAMGN

——

ImmunityBio, Inc.IBRX

——

Revenue-—

Operating income-$36.4M-45.2%

Net income-$31.8M-51.5%

EPS (diluted)-$0.46+93.4%

Cash & equivalents$49.5M-40.7%

Total debt$1.8M+90.8%

Total equity$486.7M+33.4%

Total assets$504.5M+33.8%

Operating cash flow-$23.6M-13.0%

CapEx$73.0K+462%

Free cash flow-$23.7M-13.3%

Market cap$5.03B+533%

Return on equity-27.3%-11.1pp

Debt / equity0×0.0×

Current ratio23.8×-6.3×

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Oruka Therapeutics, Inc.'s remainder of fiscal year 2024?: Oruka Therapeutics, Inc. (ORKA) reported remainder of fiscal year 2024 of $637K in Q1 2026.
How has Oruka Therapeutics, Inc.'s remainder of fiscal year 2024 changed year-over-year?: Oruka Therapeutics, Inc.'s remainder of fiscal year 2024 increased by 108.2% year-over-year, from $306K to $637K.